Key Takeaways:
Erasca, Inc. (ERAS) shares plummeted 48 percent after the company disclosed it received a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation, prompting multiple law firms to launch investigations on behalf of investors.
"The investigation is ongoing to determine whether claims may be brought under federal securities laws," Kirby McInerney LLP said in a statement. The firm is one of several, including Bragar Eagel & Squire, P.C., that announced they would be investigating the company for possible violations of federal securities laws and other unlawful business practices.
The allegations center on Erasca's ERAS-0015, a Phase-1 oral pan-RAS molecular glue inhibitor designed to target cancers. Following the disclosure on April 28, 2026, Erasca's stock price fell by $9.25 per share, closing at $9.90, down from $19.15 on the previous day. The sharp decline erased nearly half of the company's market value in a single trading session.
Law firms are now encouraging investors who purchased or otherwise acquired Erasca securities and suffered losses to come forward. The investigations are focused on whether the company and its senior management violated federal securities laws. At this stage, no lawsuit has been filed, but the inquiries could lead to a class-action suit seeking to recover damages for investors.
The drop to its lowest point since the allegations were made public tests new lows for the stock. Investors will be closely watching for any official legal filings or a formal response from Erasca's management regarding the allegations.
This article is for informational purposes only and does not constitute investment advice.
